Given that gastric tumors (especially malignant tumor types) have higher copper and lactate concentrations than normal tissues, combined treatment with copper ionophore– elesclomol and SIRT2-specific inhibitors to trigger cuproptosis obviously improves the efficacy of gastric cancer treatment. The gene discussed is SIRT2; the disease is cancer.